Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Transcript (slightly modified)
Is Express Scripts using any of the value assessment frameworks to aid in formulary decision making?
We already are using value-based concepts. We actually work very close with ICER [Institute of Clinical and Economic Review], we've also been working very closely with Peter Bach, MD, and his DrugAbacus at Memorial Sloan Kettering. And so we look at, there are going to be opportunities to actually narrow formularies in oncology in the near future, which we've never had before. But it's going to take a level of sophistication and cooperation with the oncologists that we've never had before.
How are you working with oncologists to educate them about these new frameworks?
I'll be up at ASCO in just a couple of weeks. We actually view that we have got to have relationships. We've proved with hepatitis that if we have really close working relationships with the hepatologists we could get 96% cure rates and save $1 billion. We believe that same opportunity exists in oncology.
By working closer with the oncologists on care pathways, selection of drugs, introductions of biosimilars and generics for oncologic agents, we're going to be able to find areas where we can save money but also guarantee great outcomes for patients. And that really is the aim of the project.
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More